SABCS 2021 | 12-year follow-up of SOFT and TEXT trials
Meredith M. Regan, ScD, Harvard Medical School, Boston, MA, gives an update on the 12-year follow-up results of the SOFT (NCT00066690) and TEXT (NCT00066703) trials, which investigated adjuvant endocrine therapy for premenopausal women with hormone-receptor-positive (HR+) early breast cancer. These results reported that the use of ovarian function suppression (OFS) with either tamoxifen or exemestane vs. tamoxifen alone for 5 years results in persistent long term reduction in risk of distant recurrence, with the reduction being greatest in patients who received exemestane. The use of OFS was also reported to reduce risk of death in the long-term. Dr Regan emphasises how important further follow-up of these trials is, in part due to the persistent risk of recurrence in these patients. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.
Disclosures
The SOFT and TEXT trials are coordinated by the International Breast Cancer Study Group (IBCSG), in collaboration with the Breast International Group (BIG), BIG cooperative groups, and US National Cancer Institute National Clinical Trials Network cooperative groups. Pfizer and Ipsen provided drug supply. IBCSG has received financial support for SOFT and TEXT conduct and long-term follow-up from Pfizer, Ipsen, DebioPharm, TerSera, AstraZeneca. Dr. Regan receives grant support from the Breast Cancer Research Foundation for SOFT and TEXT, and provides consulting or advisory role to Ipsen, DebioPharm, Tolmar.
